Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.35 |
| ▸ | TSHR | P16473 | 6/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16375276 | 0.88 | CYP3A4 (0.33) | USP2CYP1A2CYP3A4TSHRCYP2D6 | |
| SCHEMBL16375278 | 0.87 | USP2 (0.37) | USP2CYP1A2CYP3A4TSHRCYP2D6 | |
| SCHEMBL22685275 | 0.87 | USP2 (0.37) | USP2CYP1A2CYP3A4TSHRCYP2D6 | |
| SCHEMBL16375271 | 0.83 | USP2 (0.42) | USP2CYP1A2CYP3A4TSHRCYP2D6 | |
| SCHEMBL1753690 | 0.81 | USP2 (0.52) | USP2CYP1A2CYP3A4TSHRCYP2D6 | |
| SCHEMBL19353242 | 0.81 | — | — | |
| SCHEMBL19755635 | 0.79 | HRH3 (0.34) | USP2CYP1A2CYP3A4TSHRCYP2D6 | |
| SCHEMBL21303340 | 0.79 | — | — | |
| SCHEMBL14671083 | 0.79 | — | — | |
| SCHEMBL16659563 | 0.78 | USP2 (0.43) | USP2CYP1A2CYP3A4TSHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150203-A1 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-9458162-B2 | Cyclic molecules as bruton's tyrosine kinase inhibitors | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-10-04 | — | — | US | disclosed |
| US-20150011530-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011530-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITORS | ABL1, BTK, PRKACA | USP2 1897/4885CYP1A2 4029/4885CYP3A4 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.